Lung cancer is the primary cause of mortality in the United States and around the globe.
Therapeutic options for lung cancer treatment include surgery, radiation therapy …

Therapeutic cancer vaccines have undergone a resurgence in the past decade. A better
understanding of the breadth of tumour-associated antigens, the native immune response …

Lung cancer has a poor prognosis; over half of people diagnosed with lung cancer die
within one year of diagnosis and the 5-year survival is less than 18%. Non-small cell lung …

The transmembrane glycoprotein Mucin 1 (MUC1) is aberrantly glycosylated and
overexpressed in a variety of epithelial cancers, and plays a crucial role in progression of …

Purpose Ipilimumab, which is an anti–cytotoxic T-cell lymphocyte-4 monoclonal antibody,
showed a survival benefit in melanoma with adverse events (AEs) managed by protocol …

Importance The beneficial role of immunotherapy and the clinical relevance of current
biomarkers in non–small cell lung cancer (NSCLC) remain inconclusive; thus, appropriate …

Background Effective maintenance therapies after chemoradiotherapy for lung cancer are
lacking. Our aim was to investigate whether the MUC1 antigen-specific cancer …

Previously, clinical approaches to using the immune system against cancer focused on
vaccines that intended to specifically initiate or amplify a host response against evolving …

The immunotherapy of cancer has made significant strides in the past few years due to
improved understanding of the underlying principles of tumor biology and immunology …

Liposomes are nanocarriers comprised of lipid bilayers encapsulating an aqueous core. The
ability of liposomes to encapsulate a wide variety of diagnostic and therapeutic agents has …